Stocks › BIIB
BIOGEN INC.
BIIB·Nasdaq·
United States·USD
$249.59
+2.46 (+1.00%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BIIB
BIOGEN INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BIIBS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BIIB by members of U.S. Congress · 223 on record · 16 in the last 12 months
Whale Activity
Position changes in BIIB reported for 2026-09-30 by 1129 institutional filers
- Increased403
- New94
- Held190
- Decreased321
- Closed65
- No prior filing56
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 16.8M | $3.79B | decreased |
| BlackRock, Inc. | 16.1M | $3.63B | increased |
| PRIMECAP MANAGEMENT CO/CA/ | 15.2M | $3.43B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.7M | $2.18B | increased |
| STATE STREET CORP | 7.6M | $1.71B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6M | $1.48B | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 4.5M | $1.01B | increased |
| WELLINGTON MANAGEMENT GROUP LLP | 3.5M | $781.3M | increased |
| MORGAN STANLEY | 2.5M | $566.1M | increased |
| JPMORGAN CHASE & CO | 2.0M | $463.0M | increased |
| Invesco Ltd. | 2.0M | $445.6M | increased |
| CITADEL ADVISORS LLC | 1.6M | $359.6M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BIIB insiders, by quarter · Form 4
Recent Insider Transactions
3,337 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Minor LloydDirector | Sale | −593 | $200.96 | $119K | Aug 4, 2026 | Form 4 ↗ |
| Minor LloydDirector | Sale | −593 | $203.34 | $121K | Aug 3, 2026 | Form 4 ↗ |
| HAWKINS WILLIAM ADirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| SHERWIN STEPHEN ADirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Rowinsky Eric KDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Mantas Jesus BDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| LANGER SUSANDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Patolawala Monish DDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Pangalos Menelas NDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Pangalos Menelas NDirector | Option exercise | +2,370 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Minor LloydDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Freire Maria CDirector | Grant / award | +2,005 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Keeney AdamHead of Corporate Development | Tax withholding | −455 | $187.06 | $85K | May 1, 2026 | Form 4 ↗ |
| Keeney AdamHead of Corporate Development | Option exercise | +939 | $0.00 | $0 | May 1, 2026 | Form 4 ↗ |
| Godbout SeanChief Accounting Officer | Tax withholding | −54 | $183.78 | $10K | Apr 1, 2026 | Form 4 ↗ |
| Godbout SeanChief Accounting Officer | Option exercise | +181 | $0.00 | $0 | Apr 1, 2026 | Form 4 ↗ |
| Murphy NicoleHead of Pharm Ops and Tech | Purchase | +3 | $195.04 | $585 | Feb 12, 2026 | Form 4 ↗ |
| Singhal PriyaHead of Development | Sale | −2,660 | $199.83 | $532K | Feb 9, 2026 | Form 4 ↗ |
| Viehbacher ChristopherPresident and CEO · Director | Tax withholding | −6,624 | $201.18 | $1.3M | Feb 6, 2026 | Form 4 ↗ |
| Viehbacher ChristopherPresident and CEO · Director | Option exercise | +15.5K | $0.00 | $0 | Feb 6, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BIIB · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD PRIMECAP FUND VANGUARD CHESTER FUNDS | 8.4M | $1.81B | 1.88% | Jun 30, 2026 |
| Fidelity Contrafund | 5.0M | $1.08B | 0.60% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.7M | $1.01B | 0.04% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 3.8M | $827.0M | 0.05% | Jun 30, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $691.2M | 0.31% | Jun 30, 2026 |
| VANGUARD CAPITAL OPPORTUNITY FUND VANGUARD HORIZON FUNDS | 2.6M | $567.0M | 1.73% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 2.7M | $557.2M | 1.46% | Jul 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 2.0M | $438.8M | 0.05% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 1.9M | $415.2M | 0.05% | Aug 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 1.8M | $387.1M | 0.05% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BIIB's shares (CUSIP 09062X103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 7.6M shares5.1%
Nov 10, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 18.3M shares12.4%
Aug 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 18.3M shares12.4%
Aug 6, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 16.7M shares11.3%
Jun 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 16.7M shares11.3%
Jun 5, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 12.8M shares8.7%
May 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 12.8M shares8.7%
May 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming biogen as client
- FEDERAL STREET STRATEGIES, LLCBIOGEN, INC. · 2026 Q3 · HCR, MMM$50K
Filing ↗ - DLA PIPER LLP (US)BIOGEN, INC. · 2026 Q3 · HCR, MED, TAX, TRD$60K
Filing ↗ - BIOGENBIOGEN · 2026 Q3 · HCR, MMM, PHA, TAX$880K
Filing ↗ - TODD STRATEGY GROUPBIOGEN, INC. · 2026 Q3 · HCR, PHA$50K
Filing ↗ - FEDERAL STREET STRATEGIES, LLCBIOGEN, INC. · 2026 Q2 · HCR, MMM$50K
Filing ↗
Government Contracts
Federal awards to BIOGEN INC. · USAspending
No federal contract awards found for BIOGEN INC..
U.S. Patents
Recent USPTO applications naming BIOGEN INC.
No USPTO patent applications found for BIOGEN INC..
Annual Financials
From BIIB's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Operating income | n/a | n/a | n/a | n/a | $2.84B |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| Diluted EPS | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
| Operating cash flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B |
| Total assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B |
| Total liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B |
| Shareholders' equity | n/a | n/a | $14.80B | $13.40B | $10.90B |
As BIOGEN INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 6, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 3-for-1Stock splitJan 18, 2001
- 2-for-1Stock splitDec 21, 1999
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsOct 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 29, 2026
EDGAR ↗ - 8-K · Items 2.02Results of operationsJul 1, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 10, 2026
EDGAR ↗ - 8-K/A · Items 9.01Jun 10, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.01, 2.03, 7.01, 9.01Material agreement · Acquisition or disposition · Direct financial obligationMay 14, 2026
EDGAR ↗
About BIOGEN INC.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0000875045 ↗
Former namesBIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE






